Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 11/20 | 0.41 |
| ▸ | TACR3 | P29371 | 1/20 | 0.41 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TOP2A | P11388 | 1/20 | 0.38 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14183159 | 0.93 | TACR3 (0.41) | ELANETACR3BRD9SYKNPC1 | |
| SCHEMBL4878114 | 0.83 | MGLL (0.40) | ELANESYKTOP2ATOP2BMAPT | |
| SCHEMBL5109252 | 0.82 | TACR3 (0.42) | ELANETACR3BRD9SYKNPC1 | |
| SCHEMBL4804689 | 0.81 | POLB (0.43) | ELANESYKNPC1RAB9ATOP2A | |
| SCHEMBL4804680 | 0.81 | POLB (0.43) | ELANESYKNPC1RAB9ATOP2A | |
| SCHEMBL14183149 | 0.78 | BRD9 (0.50) | BRD9 | |
| SCHEMBL2209322 | 0.77 | NPC1 (0.40) | ELANESYKNPC1RAB9ATOP2A | |
| SCHEMBL2209326 | 0.77 | NPC1 (0.40) | ELANESYKNPC1RAB9ATOP2A | |
| SCHEMBL14183135 | 0.76 | MGLL (0.39) | ELANETACR3SYKTOP2ATOP2B | |
| SCHEMBL4876178 | 0.76 | KLK5 (0.46) | TACR3BRD9SYKMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368458-B2 | Bicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-06 | — | — | US | disclosed |
| US-20060155126-A1 | Bicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060155126-A1 | Bicyclic heterocycles as cannabinoid receptor modulators | CNR1, CNR2, GPR18 | ELANE 3989/4885TACR3 259/4885BRD9 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.